ClinicalTrials.gg
CompletedNCT06717425Updated Feb 6, 2026

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

A Phase 2 interventional study of PF-07976016 and Placebo in Obesity, sponsored by Pfizer. Completed at 38 sites in 3 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Obesity by Pfizer — 13 open to participants now, 19 under way, 12 of them phase 3. Obesity · Pfizer.

Enrollment
20th of 62
263 · median 127
Started
2024
with 6 others
Phase 2
11 of 64
none open now
Registered
38th of 64
by date

Among the 64 studies in Obesity by Pfizer, this one is the 20th largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2024, is one of 11 in phase 2, and was the 38th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 64 studies in Obesity by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Obesity by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants who take placebo (a lookalike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight and how well they tolerate the study medicine.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or non-pregnant, non-breastfeeding female, 18 to 74 years of age at Visit 1
  • ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as \<5 kg change in the 12 weeks before Visit 1
  • Eligible and willing to receive required background medicine
  • Willing and able to comply with all study procedures

Key Exclusion Criteria:

  • Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes.
  • Use of any prohibited prior or concomitant medication(s)
  • Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests at Visit 1.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    PF-07976016 Dose 1

    Drug: PF-07976016

  • Experimental
    PF-07976016 Dose 2

    Drug: PF-07976016

  • Experimental
    PF-07976016 Dose 3

    Drug: PF-07976016

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Taken once daily

  • DrugPlacebo

    Taken once daily

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in body weight

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Number of participants with treatment emergent adverse events

    Time frame: From first dose (Day 1) up to 28-35 days after final dose, a total of approximately 21 weeks

07

Study locations

38 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Clinical & Translational Research Center
    Aurora, Colorado 80045, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • St Johns Center for Clinical Research
    Saint Augustine, Florida 32086, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • AMR Clinical
    Norman, Oklahoma 73069, United States
  • Cornerstone Nutrition and Diabetes
    Norman, Oklahoma 73069, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Elligo Clinical Research Center
    Austin, Texas 78704, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78749, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
  • Southwest Internal Medicine, PC
    St. George, Utah 84790, United States
  • Selma Medical Associates
    Winchester, Virginia 22601, United States
  • Ocean West Research Clinic
    Surrey, British Columbia V3Z 2N6, Canada
  • Dawson Clinical Research Inc.
    Guelph, Ontario N1H 1B1, Canada
  • The Wharton Medical Clinic Clinical Trials Inc.
    Hamilton, Ontario L8L 5G8, Canada
  • Milestone Research Inc.
    London, Ontario N5W 6A2, Canada
  • Canadian Phase Onward
    Toronto, Ontario M3J 0K2, Canada
  • Centrum Zdrowia Metabolicznego Pawel Bogdanski
    Poznan, Greater Poland Voivodeship 60-589, Poland
  • Medicome Sp. z o. o.
    Oświęcim, Lesser Poland Voivodeship 32-600, Poland
  • Ekamed
    Lublin, Lublin Voivodeship 20-718, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o.
    Gdansk, Pomeranian Voivodeship 80-546, Poland
  • Centrum Medyczne Pratia Gdynia
    Gdynia, Pomeranian Voivodeship 81-338, Poland
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Oct 2025, 10 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 10 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Dec 5, 2024
StartActual
Dec 9, 2024
Primary completionActual
Oct 23, 2025
CompletionActual
Jan 12, 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06717425
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 5, 2024
Start date
Dec 9, 2024
Primary completion
Oct 23, 2025
Completion
Jan 12, 2026
Last update
Feb 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-07976016

Start the discussion